{"product_id":"gilead-swot-analysis","title":"Gilead Sciences SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGilead Sciences shows strong antiviral leadership and a deep pipeline, but faces revenue concentration and pricing scrutiny, while opportunities in oncology and novel modalities contrast with threats from generics and regulatory pressure. Our full SWOT unpacks financial context, strategic levers, and risk mitigation. Discover actionable insights and a ready-to-use report—purchase the complete SWOT analysis for Word and Excel deliverables.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeadership in antiviral therapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead’s decades of virology expertise underpin a dominant position in HIV, HBV and HCV therapies, with flagship HIV regimens driving recurring revenue and strong provider trust. Biktarvy and other integrase-based regimens anchor commercial performance and enable lifecycle management through fixed-dose combos and line extensions. Scale in trials, manufacturing and global access programs accelerates uptake of new antivirals and reduces unit costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpanding oncology footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead has diversified beyond virology via antibody-drug conjugate Trodelvy (sacituzumab govitecan, acquired with Immunomedics in 2020) and CAR-Ts from Kite (Yescarta, Tecartus, acquired 2017), enabling multiple solid and hematologic indications; ongoing label expansions and earlier-line studies plus biomarker-driven trials and established oncology networks increase pipeline optionality and upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust cash flow and capital allocation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRobust operating cash flow—approximately $8.7 billion in 2024—funds Gilead’s R\u0026amp;D, BD\/M\u0026amp;A, dividends and sizable buybacks, sustaining strategic investment without diluting equity. A resilient balance sheet with multi-billion dollar liquidity supports long-horizon programs and bolt-on deals, enabling financial flexibility to bridge patent cliffs and absorb clinical volatility. This firepower underwrites global launch capabilities and strengthens market-access negotiations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal scale and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGilead leverages established distribution, payer relationships and tender expertise to accelerate regional launches, supported by scale reflected in 2023 revenue of $27.3 billion. Tiered pricing and partnerships expand access in low- and middle-income markets, while manufacturing scale improves supply reliability and cost efficiency. Deep KOL engagement drives guideline inclusion and formulary wins across major therapeutic areas.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstablished distribution and tender know-how\u003c\/li\u003e\n\u003cli\u003eTiered pricing + partnerships for LMIC access\u003c\/li\u003e\n\u003cli\u003eScale: supply reliability and lower unit costs\u003c\/li\u003e\n\u003cli\u003eKOL engagement → guideline and formulary gains\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative long-acting and curative ambitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGilead pursues long-acting and curative ambitions—Sunlenca (lenacapavir) approved 2022 offers twice‑yearly dosing for MDR HIV—while HBV functional cure programs target WHO’s ~296 million chronic carriers. Such profiles can materially improve adherence, lower resistance, and create durable competitive moats if safety and convenience are confirmed. Successful execution would reshape standard‑of‑care and extend product lifecycles.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStep‑change outcomes: long‑acting + cure focus\u003c\/li\u003e\n\u003cli\u003eAdherence\/resistance: less frequent dosing, lower resistance risk\u003c\/li\u003e\n\u003cli\u003eMarket impact: HIV market ~30B, HBV pool ~296M patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVirology and oncology momentum fuels \u003cstrong\u003e$27.3B\u003c\/strong\u003e revenue and \u003cstrong\u003e$8.7B\u003c\/strong\u003e operating cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead’s virology leadership and oncology portfolio (Trodelvy, Yescarta) drive recurring revenue and guideline momentum. 2023 revenue $27.3B and 2024 operating cash flow ~$8.7B fund R\u0026amp;D, BD and buybacks. Long‑acting Sunlenca and HBV cure programs expand market optionality across a ~$30B HIV market and ~296M HBV carriers. Global scale lowers unit costs and improves LMIC access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (2023)\u003c\/td\u003e\n\u003ctd\u003e$27.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating CF (2024)\u003c\/td\u003e\n\u003ctd\u003e$8.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV market\u003c\/td\u003e\n\u003ctd\u003e~$30B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHBV chronic carriers\u003c\/td\u003e\n\u003ctd\u003e~296M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey assets\u003c\/td\u003e\n\u003ctd\u003eBiktarvy, Sunlenca, Trodelvy, Yescarta\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Gilead Sciences’ internal and external business factors, outlining strengths, weaknesses, opportunities, and threats that shape its competitive position and future growth in the biopharma sector.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT matrix tailored to Gilead Sciences for rapid strategic alignment, highlighting strengths in antiviral leadership, weaknesses from patent cliffs and pipeline concentration, opportunities in oncology and long‑acting therapies, and threats from competitive biosimilars and regulatory pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue concentration in HIV\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDependence on a handful of HIV regimens—still accounting for ≈40% of Gilead's 2024 revenue—raises LOE and competitive risk. Payer pushback or emergence of a rival long-acting standard could rapidly erode share and pricing. Any safety signal in HIV drugs would have outsized financial impact given concentration. Diversification into oncology and antivirals is progressing but remains less mature than virology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHCV franchise erosion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCurative direct-acting antivirals have shrunk the treatable pool: WHO estimates about 58 million people live with chronic HCV globally, down from earlier projections, driving secular revenue decline for Gilead. Screening and linkage-to-care gaps—CDC estimates ~2.4 million people with HCV in the US—limit new treatment starts. Competitive pricing and generic competition in many markets compress margins, leaving the franchise as a cash-generating but low-growth asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology execution risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eADCs and cell therapies carry complex manufacturing, cold‑chain logistics and safety management that increase failure risk and unit costs; CAR‑T list prices typically range from about 373,000 to 475,000 per patient. Success depends on label expansions, head‑to‑head superiority and earlier‑line adoption to drive volume. Trial setbacks or competing readouts can rapidly stall momentum and market access. Commercial ramp requires substantial upfront investment and payer education, with the CAR‑T\/ADC market still scaling at an estimated ~25–30% CAGR.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent and litigation overhangs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKey assets face staggered LOEs across 2026–2033 and ongoing IP challenges that threaten franchise value; adverse rulings or settlements could accelerate erosion of revenue (Gilead reported roughly $27.6B in 2024 revenue). Litigation diverts management focus and adds legal and settlement costs, while uncertainty complicates long-term forecasting and contracting.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLOE window 2026–2033\u003c\/li\u003e\n\u003cli\u003e2024 revenue ~$27.6B\u003c\/li\u003e\n\u003cli\u003eLitigation-driven costs and distraction\u003c\/li\u003e\n\u003cli\u003eForecasting and contracting uncertainty\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing and reimbursement sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHigh-cost specialty drugs draw intense payer and policymaker scrutiny; step edits, mandatory rebates and reference pricing commonly reduce net prices by 20–40%.\u003c\/p\u003e\n\u003cp\u003eUS Medicare negotiation under the Inflation Reduction Act and global austerity measures heighten pricing pressure ahead of 2026 negotiating rounds.\u003c\/p\u003e\n\u003cp\u003eAccess delays and coverage restrictions can cut first-year uptake, often slicing launch year sales by over 30%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePricing cuts: 20–40% net price erosion\u003c\/li\u003e\n\u003cli\u003ePolicy risk: Medicare negotiation expanding by 2026\u003c\/li\u003e\n\u003cli\u003eLaunch impact: \u0026gt;30% first-year sales loss from delays\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHIV LOE (2026-33) risks \u003cstrong\u003e40%\u003c\/strong\u003e of 2024 revenue; HCV, CAR-T margins.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentration: HIV regimens ≈40% of 2024 revenue ($27.6B), creating acute LOE and competitive risk across 2026–2033.\u003c\/p\u003e\n\u003cp\u003eHCV franchise shrinking: WHO ~58M chronic HCV globally; US ~2.4M untreated, pricing and generics compressing margins 20–40%.\u003c\/p\u003e\n\u003cp\u003eNew oncology\/CAR‑T work faces high manufacturing, launch and payer hurdles; CAR‑T list prices ≈$373k–$475k per patient.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$27.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV share\u003c\/td\u003e\n\u003ctd\u003e≈40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLOE window\u003c\/td\u003e\n\u003ctd\u003e2026–2033\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCV prevalence\u003c\/td\u003e\n\u003ctd\u003e~58M global; ~2.4M US\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice erosion\u003c\/td\u003e\n\u003ctd\u003e20–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAR‑T list price\u003c\/td\u003e\n\u003ctd\u003e$373k–$475k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eGilead Sciences SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis of Gilead Sciences you'll receive upon purchase—no surprises, just professional quality. The preview below is pulled directly from the final, editable report. Buy now to unlock the complete, detailed version ready for download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56164271817081,"sku":"gilead-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/gilead-swot-analysis.png?v=1762729429","url":"https:\/\/portersfiveforce.com\/products\/gilead-swot-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}